Pacific Consolidated Industries LLC

Pacific Consolidated Industries LLC, doing business as PCI, manufactures ruggedized onsite liquid and gaseous oxygen and nitrogen generation systems and related medical equipment as a prime contractor (97% of recent awards) to the Defense Logistics Agency and other federal agencies. PCI is a for-profit limited liability company headquartered in Riverside, California, with no SBA set-aside designations, competing predominantly in full-and-open procurements, though a material share of recent awards carry total small business set-asides. The company specializes in compressor units, oxygen and nitrogen generation equipment, patient oxygen distribution systems, surgical suite oxygen systems, filters, valves, radiators, hoses, gaskets, tubing, and liquid quantity gauges across NAICS 333612 (Air and Gas Compressor Manufacturing) and related product/service codes.

PCI's customer concentration is extreme and functionally single-customer. The Defense Logistics Agency Troop Support Medical (DLA Medical Supply Chain) accounts for 604 awards valued at $1.5 billion in combined potential value—80% of the vendor's entire footprint. DLA Land and Maritime accounts for an additional 413 awards worth $72.2 million. These two DLA divisions together represent 76% of all awards by count and 87% of combined potential value. The next four customer agencies (DLA Construction and Equipment, DLA Aviation, the Navy Naval Air Systems Command, and Naval Sea Systems Command) collectively represent less than 5% of the dollar value. Representative prime work includes a $294,490 delivery order from DLA Land and Maritime for a compressor unit (awarded April 13, 2026), a $1.12 million delivery order from DLA Medical Supply Chain for EDOCS oxygen generation systems (awarded October 21, 2025), a $3.34 million firm fixed-price definitive contract from the Air Force Aeronautical Systems Center for SESS carts (awarded August 7, 2025), a $1.96 million purchase order from the Army Corps of Engineers for a PCI DOCS oxygen generator (awarded September 27, 2023), and a $1.52 million sole-source purchase order from the Defense Health Agency for EDOCS special tools and consumable kits (awarded September 30, 2024).

PCI holds three major indefinite delivery contracts with DLA Medical Supply Chain: a $356 million single-award IDC for medical capital equipment (awarded October 16, 2024, through October 2034), a $999,999,999 single-award IDC for noncommercial medical equipment (awarded October 16, 2024, through October 2034), and a $1.63 billion cumulative IDC portfolio across DLA Medical Supply Chain extending through 2030 and beyond. Smaller single-award IDCs with DLA Land and Maritime cover compressor units ($14.7 million, awarded May 2025), radiators ($250,000), gaskets ($250,000), and nonmetallic hose assemblies ($250,000). These vehicles generate the bulk of task order activity: 278 task orders under one DLA Medical Supply Chain IDC alone, 111 under another DLA vehicle, and 97 under a third.

Activity has declined year over year—206 awards in 2022 down to 30 in 2026 (five months through the snapshot date)—suggesting either a portfolio contraction or a shift toward larger-dollar, fewer-award delivery orders against the massive $356 million and $1 billion IDCs. Six awards totaling $3.2 million in combined potential value face ultimate completion within the next twenty-four months, presenting recompete exposure concentrated in the DLA Land and Maritime compressor and components space.

PCI subcontracts to major defense primes including BAE Systems (nine awards for F-16 support equipment oxygen and nitrogen generation plants and spares kits for Ukraine, Bulgaria, Morocco, and internal platforms, 2024–2026), Lockheed Martin (nitrogen generation, filter elements, and developmental flight testing infrastructure support, 2024–2025), General Atomics Aeronautical Systems (MQ-9 Predator Reaper contractor logistics support components, July 2024), and Sierra Nevada Company (nitrogen booster for Big Safari, October 2024). The sub footprint is small (45 awards, 3% of total) but strategically placed on high-visibility programs, signaling PCI's role as a specialized gas-generation and oxygen-distribution supplier to tier-one integrators.

PCI's federal footprint rests on a single, dominant customer relationship (DLA Medical Supply Chain) that carries near-total concentration risk. The company has shipped more than $292.7 million in actual obligations across $1.88 billion in combined potential value, indicating that 1,629 awards—many small, recurring delivery orders—fund ongoing medical logistics operations. As a manufacturer of proprietary systems (particularly EDOCS, DOCS, and related oxygen generators), PCI holds defensible sole-source and small-business-set-aside positions within DLA's medical supply chain but faces material recompete exposure if DLA's procurement strategy or requirements shift.

LOX/LIN generating plants and their spares and accessories including air separation plants, SGNSC/SESSC units, the NitroGenie. Also product support and training.